BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
The speakers for the e-conference are: Dr. Mukund Chorgade, President/CSO, THINQ Pharma; Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance; Jayaseelan J., National Vice President (Industry Division), Indian Pharmaceutical Association; Spandan Mishra who is Director- Sales, Customer Service & Logistics for Evonik India, Nepal & Sri Lanka region; Dr. Kommu Nagaiah, Chief Scientist & Head, CSIR-IICT; Govind K. Jaju, Partner, Suingora Consulting; nd Pravin Prashant, Executive Editor, Indian Pharma Post & Editor, Indian Chemical News.
Lupin has reported consolidated financial results for the period ended December 31, 2021
Allocation for the healthcare sector has gone up but is still woefully short of expectations. A few leading voices from the hospital and consulting sectors share their perspective on what they expect from Budget 2022
The vaccines are currently only authorised for emergency use in the country
Direct to consumer pharmacy and formation as pharmacy benefit manager further mission to drastically expand access to affordable pharmaceuticals
Torrent Pharmaceuticals has reported consolidated financial results for the period ended December 31, 2021.
The stability is led by healthy demand in the domestic and emerging markets
Subscribe To Our Newsletter & Stay Updated
